4
Changes in Ownership
Denali Therapeutics Inc. Filed Acc 0001714899-24-000156
Director sold 30,688 shares at an average $22.11 ($678,660)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Krognes Steve E. · Director
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-06-13 | Sale : show line 1 in the form 10b5-1 | −688 | $21.79 | $14,992 | 52,620 | D |
| 2024-07-01 | Sale : show line 2 in the form 10b5-1 | −29,900 | $22.12 | $661,388 | 34,504 | D |
| 2024-07-01 | Sale : show line 3 in the form 10b5-1 | −100 | $22.80 | $2,280 | 34,404 | D |
| Open-market sales · 30,688 sh · avg $22.11 · $678,660 | ||||||
Loading xslF345X05/wk-form4_1720055619.xml…